Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Non-Current Assets (2016 - 2025)

Iradimed (IRMD) has disclosed Non-Current Assets for 13 consecutive years, with $29.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 49.31% to $29.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $108.6 million, a 58.21% increase, with the full-year FY2024 number at $23.1 million, up 42.89% from a year prior.
  • Non-Current Assets was $29.8 million for Q3 2025 at Iradimed, up from $29.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $29.8 million in Q3 2025 to a low of $6.6 million in Q4 2021.
  • A 5-year average of $14.7 million and a median of $15.3 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: dropped 20.57% in 2021, then skyrocketed 112.21% in 2023.
  • Iradimed's Non-Current Assets stood at $6.6 million in 2021, then rose by 20.91% to $8.0 million in 2022, then soared by 101.33% to $16.2 million in 2023, then surged by 42.89% to $23.1 million in 2024, then rose by 29.11% to $29.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Non-Current Assets are $29.8 million (Q3 2025), $29.1 million (Q2 2025), and $26.6 million (Q1 2025).